NasdaqCM - Delayed Quote USD

Jasper Therapeutics, Inc. (JSPR)

22.03 -0.08 (-0.36%)
At close: April 24 at 4:00 PM EDT
21.64 -0.39 (-1.77%)
After hours: April 24 at 4:42 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Ronald A. Martell President, CEO & Director 892.45k -- 1962
Mr. Herbert C. Cross CFO & Corporate Secretary -- -- 1972
Dr. Luca Di Noto Ph.D. Senior Vice President of Technical Operations -- -- --
Mr. David Ku M.D. Vice President of Corporate Development, Portfolio Strategy & Management -- -- --
Mr. Matthew Ford Vice President of Human Resources -- -- --
Dr. Wendy Pang M.D., Ph.D. Senior Vice President of Research & Translational Medicine -- -- --
Dr. Edwin Jonathan Tucker M.D. Chief Medical Officer -- -- 1972
Ms. Patricia Carlos Senior Vice President of Regulatory Affairs & Quality -- -- --

Jasper Therapeutics, Inc.

2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400 https://www.jaspertherapeutics.com/
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
45

Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Corporate Governance

Jasper Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
Jasper Therapeutics, Inc. Earnings Call

Related Tickers

CLDX Celldex Therapeutics, Inc.
37.02
-1.99%
 
TRML Tourmaline Bio, Inc.
15.41
+2.12%
 
APGE Apogee Therapeutics, Inc.
46.54
-6.49%
 
FDMT 4D Molecular Therapeutics, Inc.
24.25
-2.26%
 
IGMS IGM Biosciences, Inc.
7.96
+3.38%
 
ZURA Zura Bio Limited
3.3100
-4.89%
 
MRUS Merus N.V.
41.97
+2.82%
 
LPTX Leap Therapeutics, Inc.
3.2900
+2.81%
 
PEPG PepGen Inc.
11.83
+0.94%
 
SYRE Spyre Therapeutics, Inc.
32.99
-3.68%